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Abstract 
A series of triphenylethylene bisphenol analogues of the selective estrogen receptor 
modulator (SERM) tamoxifen were synthesized and evaluated for their abilities to inhibit 
aromatase, bind to estrogen receptor-α (ER-α) and estrogen receptor-β (ER-β), and antagonize 
the activity of β-estradiol in MCF-7 human breast cancer cells.  The long-range goal has been to 
create dual aromatase inhibitor (AI)/selective estrogen receptor modulators (SERMs).  The 
hypothesis is that in normal tissue the estrogenic SERM activity of a dual AI/SERM could 
attenuate the undesired effects stemming from global estrogen depletion caused by the AI 
activity of a dual AI/SERM, while in breast cancer tissue the antiestrogenic SERM activity of a 
dual AI/SERM could act synergistically with AI activity to enhance the antiproliferative effect. 
The potent aromatase inhibitory activities and high ER-α and ER-β binding affinities of several 
of the resulting analogues, together with the facts that they antagonize β-estradiol in a functional 
assay in MCF-7 human breast cancer cells and they have no E/Z isomers, support their further 
development in order to obtain dual AI/SERM agents for breast cancer treatment.  
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INTRODUCTION 
Aromatase (also known as CYP19) is a member of the general class of cytochrome P450 
enzymes. It catalyzes the conversion of androgens to estrogens, which is a crucial step in the 
biosynthesis of estrogens in the human body.1 Aromatase inhibitors (AIs) have been widely used 
for treatment of hormone receptor-positive breast cancer in postmenopausal women. Currently, 
three AIs [letrozole (1), anastrozole (2) and exemestane (3), Figure 1] have been approved by the 
FDA. Comparative clinical trials involving postmenopausal women with breast cancer have 
demonstrated that AIs are superior to the selective estrogen receptor modulator (SERM) 
tamoxifen (4) (Figure 1), which, as with other SERMs, blocks estrogen receptors in breast cancer 
tissue while stimulating them in a variety of normal tissues.2-6 In the five-year ATAC (Arimidex, 
Tamoxifen, Alone, or in Combination) trial, the use of anastrozole alone resulted in a 13% 
improvement of disease-free survival, 21% reduction in the time-to-recurrence, 42% reduction in 
occurrence of contralateral breast cancer and 14% reduction in risk of distant metastasis when 
compared to tamoxifen alone.4 The use of AIs is also reported to cause fewer vaginal bleeding 
events, thromboembolic events, and endometrial cancer occurrences than tamoxifen.4-6 However, 
the use of AIs is associated with serious side effects. Since AIs nonselectively deplete estrogen in 
the whole body, they lead to severe musculoskeletal pain, reduction of bone density, and an 
increased frequency of bone fractures and cardiovascular events.7-11 According to the five-year 
ATAC trial, anastrozole treatment led to a higher incidence of bone fractures (11% vs 7.7%) and 
arthralgia (35.6% vs 29.4%) than tamoxifen.4 The increased musculoskeletal pain caused by AIs 
negatively impacts patient compliance. Reported AI discontinuation rates attributed to severe 
musculoskeletal symptoms range from 13-52%.12-14 Non-adherence rates are also high.15, 16 For 
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example, observations from three data sets indicate that only 62-79% of women adhere (take 
anastrazole more than 80% of the days during the treatment period) after three years.16 
Figure 1. The structures of the aromatase inhibitors letrozole, anastrozole, exemestane, and the 
selective estrogen receptor modulator tamoxifen.  
One possible approach to improve the efficacy and decrease the side effects associated 
with AIs is to build SERM activity into them. The estrogenic activity of a dual AI/SERM due to 
binding to and stimulation of estrogen receptors (ERs) in non-cancerous musculoskeletal tissue 
could counteract some of the negative effects of the dual AI/SERM that result from global 
estrogen loss due to aromatase inhibition.  On the other hand, the antagonistic blockade of ERs in 
breast cancer cells by a dual AI/SERM might act synergistically with the decrease in estrogen 
concentration due to aromatase inhibition, assuming that the inhibition of estrogen production is 
not totally complete.  In other words, as with the SERMs, the ER agonist effect of a dual 
AI/SERM would be beneficial in normal, non-cancerous musculoskeletal tissue relative to an AI 
alone by decreasing the side effects that result from estrogen depletion, while the ER antagonist 
effects of a dual AI/SERM would be beneficial in breast cancer cells by blocking the effect of 
residual estrogen resulting from incomplete aromatase inhibition. In fact, according to Brodie et 
al., a combination of the aromatase inhibitor letrozole and the estrogen receptor antagonist/down-
regulator fulvestrant was more effective than either letrozole or fulvestrant alone in suppressing 
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breast tumor growth and in delaying the development of tumor resistance.17-19  In that case, the 
delay in development of resistance was thought to result from down-regulation of the ER by 
fulvestrant and an associated down-regulation of signaling proteins that play a role in the 
maintenance of hormonal resistance.19 Meanwhile, it is also possible that the estrogenic 
component of the SERM activity of a dual AI/SERM agents could stimulate estrogen receptors 
in non-cancerous musculoskeletal tissues and ameliorate the side effects caused by estrogen 
depletion of conventional AIs (e.g. osteoporosis, musculoskeletal pain, and bone fractures). In 
fact, according to the ATAC trail, a combination of anastrozole with tamoxifen resulted in fewer 
fractures than when anastrozole was used alone.20  As expected, the combination resulted in 
more fractures than tamoxifen alone, indicating that the fractures were the result of the AI and 
not the SERM.20 For these reasons, dual AI/SERM agents could possibly have superior efficacy 
and decreased side effects compared to conventional AIs alone.  However, the combination of 
anastrozole with tamoxifen resulted in a greater incidence of endometrial cancer (0.3%) than 
anastrozole alone (0.1%), and in this regard it may be better to combine raloxifene-type SERM 
activity than tamoxifen-type SERM activity with an AI (different SERMs produce unique spectra 
of agonist activities in different normal tissues because they have different affinities for ER-
α and ER-β, which are expressed to different extents in various tissues, and the consequences of 
binding to ER-α and ER-β are different).21  Although the ATAC trial showed no therapeutic 
advantage of a specific tamoxifen plus anastrozole combination with regard to anticancer 
activity,20 this result should not be generalized to all SERM plus AI combinations or to a 
hypothetical dual AI/SERM agent.  Of note, the serum concentration of anastrozole, a relatively 
weak aromatase inhibitor, was 27% lower in the combination arm of the ATAC trial, although it 
was claimed that this was of no pharmacological significance.22
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Norendoxifen is a metabolite of tamoxifen, and it is also a potent aromatase inhibitor.23 
The synthesis of (E,Z)-norendoxifen (5) was reported in 2013.24 Biological testing results 
confirmed the aromatase inhibitory activity of (E,Z)-norendoxifen and further established high 
affinity for both ER-α and ER-β (Figure 2), establishing (E,Z)-norendoxifen the first substance 
with potential dual AI and ER binding activity.24, 25 The E- and Z-norendoxifen isomers (E-5 and 
Z-5) were also prepared via stereoselective synthetic routes, and their biological activities 
revealed that E-norendoxifen is the more potent aromatase inhibitor, while Z-norendoxifen 
displayed greater affinity for both ER-α and ER-β.24 To optimize efficacy and CYP selectivity, a 
series of norendoxifen analogues were subsequently designed and prepared using a structure-
based drug design approach. This led to the discovery of 4'-hydroxynorendoxifen (6), which has 
elevated potency against aromatase and higher affinity for ER-α and ER-β. It is also a more 
potent antagonist of estradiol-stimulated progesterone receptor mRNA expression in MCF-7 
cells compared to norendoxifen.26  
Figure 2. The structures and biological activities of (E,Z)-norendoxifen, Z-norendoxifen, E-
norendoxifen and 4'-hydroxynorendoxifen. 
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Like 4-hydroxytamoxifen, most norendoxifen analogues undergo facile E/Z 
isomerization in solution.24 Although the detailed mechanism is still controversial, the E/Z 
isomerization is considered to be facilitated by the presence of a phenolic hydroxyl group in one 
of the para positions.27 The rate of isomerization speeds up as the number of para phenolic 
hydroxyl group increases, and the rate is also dependent on the solvent and temperature.28 The 
E/Z isomerization makes the preparation of pure E and Z isomers of norendoxifen analogues 
difficult. Moreover, since isomerization happens both in stock solutions and during biological 
testing, it also influences the accuracy of the biological testing results for pure E and Z isomers. 
To develop more promising norendoxifen analogues for treatment of breast cancer, it is 
important to prepare analogues as pure E and Z isomers. A mixture of E and Z isomers would 
complicate the pharmacological profiles and limit the use of the drugs because the E and Z 
isomers would be expected to have different biological activities against aromatase, ERs and 
other CYPs. This argument is in fact supported by results derived from testing tamoxifen, which 
document different relative binding affinities of the two isomers for the ER, as well as different 
agonist vs. antagonist properties as monitored by uterine weight.29  Furthermore, the 
isomerization of (Z)-4-hydroxytamoxifen to its less active isomer is thought to contribute to 
tamoxifen resistance.30   
To overcome the problem presented by E/Z isomerization, a series of triphenylethylene 
bisphenol analogues were designed by eliminating the aminoethoxy side chain of norendoxifen, 
thus resulting in two identical substituents on one end of the double bond and eliminating the 
possibility of E/Z isomers. This allowed a straightforward evaluation of the aromatase inhibitory 
activities, ER-α and ER-Β binding affinities, and abilities of the compounds to antagonize β-
estradiol-stimulated transcriptional activity in MCF-7 human breast cancer cells. The results of 
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these studies will facilitate the development of a new generation of dual AI/SERM agents for 
breast cancer treatment.  
RESULTS AND DISCUSSION 
Design of Triphenylethylene Bisphenol Analogues. Compound 7 is a weak aromatase 
inhibitor, and it also shows moderate binding affinities to ER-α and ER-β (Table 1).24 This 
substance is also a good ER antagonist without significant agonistic side effects in MCF-7-2a 
cells.31 Based on the structure of compound 7, the following structural modifications were 
explored to improve the potency (Figure 3). (1) Incorporation of hydrogen bond donors 
(hydroxyl or amino groups) on the meta or para positions of the "A" ring. (2) Introduction of 
iron-coordinating groups (nitrile, imidazole or triazole groups) in the location of the ethyl group. 
Hydrogen bond donors on the "A" ring can be expected to form hydrogen bonds with aromatase 
and the ERs, while iron-coordinating groups could improve aromatase inhibitory activity by 
coordinating to the iron of aromatase. 
Figure 3. The design strategy for triphenylethylene bisphenol analogues. 
Synthesis. A short and efficient synthetic route was established to prepare analogues with an 
iron-coordinating group in the location of the ethyl side chain (Scheme 1). The bisphenol 9 was 
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first prepared by McMurry cross-coupling of acetophenone (8) with 4,4'-
dihydroxybenzophenone as described.25 The bisphenol 9 was treated with an excess of MOMCl 
to afford the di-protected product 10 in good yield. The protected intermediate 10 underwent a 
series of reactions, including bromination with NBS, alkylation of potassium cyanide, and 
deprotection of the MOM groups with HCl to afford the nitrile 11 in very good yield. The 
imidazole product 12 and triazole compound 13 were also obtained in good yield by treating 10 
with similar sequential reactions, including bromination with NBS, alkylation of imidazole or 
1,2,4-triazole, and cleavage of the phenols. 
Scheme 1. Synthesis of Analogues 11-13a 
aReagents and conditions: (a) 4,4'-dihydroxybenzophenone, Zn, TiCl4, THF; (b) NaH, MOMCl, 
THF; (c) NBS, CCl4; (d) KCN, THF, H2O; (e) methanol, HCl; (f) NaH, imidazole, THF; (g) 
NaH, 1,2,4-triazole, THF.  
Analogues 17a, 18a, 19a and 20a were designed by incorporating a hydroxyl group on the 
“A” ring to probe the importance of a hydrogen bond donor in the para position. For analogues 
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17b, 18b, 19b and 20b, a fluorine atom was introduced ortho to the "A" ring hydroxy group. The 
presence of the electronegative fluorine atom would increase the acidity of the hydroxy group 
and enable stronger hydrogen bonds to be formed. To prepare analogues 17-20, the 
corresponding hydroxylated acetophenones 14a-b were first protected with a pivaloyl group and 
the product reacted with 4,4'-dihydroxybenzophenone under the McMurry cross-coupling 
conditions to provide the bisphenols 15a-b (Scheme 2). The phenolic hydroxyl groups were 
protected by MOM groups to afford 16a-b. Compounds 16a-b were brominated with NBS, 
followed by alkylation of KCN, to install the nitrile group. Unexpectedly, the pivaloyl group was 
also cleaved under the alkylation reaction conditions. In the next step, the MOM protecting 
groups were removed with HCl to directly provide the products 17a-b. To prepare the imidazole 
products 18a-b, compounds 16a-b underwent a series of sequential reactions including 
bromination with NBS, alkylation of imidazole, deprotection of the pivaloyl group with KOH 
and removal of the MOM groups under acidic conditions to afford 18a-b in good yield. 
Interestingly, subjection of 16a-b to a similar sequence of reactions incorporating 1,2,4-triazole 
instead of imidazole led to the production of two isomers in each case (i.e. 19a and 20a were 
obtained from 16a, and 19b and 20b were obtained from 16b) due to the presence of two 
nonequivalent nucleophilic nitrogens in the 1,2,4-triazole system vs. only one for the imidazole 
case. Compounds 19a and 19b were isolated as the major products, and compounds 20a and 20b 
were the minor products.  
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Scheme 2. Synthesis of Analogues 17-20a 
aReagents and conditions: (a) NaH, PvCl, THF; (b) 4,4'-dihydroxybenzophenone, Zn, TiCl4, 
THF; (c) NaH, MOMCl, THF; (d) NBS, CCl4; (e) KCN, THF, H2O; (f) methanol, HCl; (g) NaH, 
imidazole, THF; (h) KOH, THF, H2O; (i) NaH, 1,2,4-triazole, THF. 
In order to prepare analogues with an amino group in the para position of the "A" ring, 4-
aminoacetophenone (21) was reacted with the di-protected 4,4'-dihydroxybenzophenone 22 
under McMurry cross-coupling reaction conditions to afford 23 (Scheme 3). The amino group 
was protected with a Boc group, and the product 24 was subjected to a series of sequential 
reactions, including bromination with NBS, alkylation of KCN (both pivaloyl groups were 
cleaved under these conditions) and removal of the Boc group with HCl to afford the product 25 
in very good yield. The imidazole product 26 and triazole products 27 and 28 were also obtained 
by subjecting 24 to a similar set of reactions. 
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Scheme 3. Synthesis of Analogues 25-28a 
 
aReagents and conditions: (a) Zn, TiCl4, THF; (b) Boc2O, dioxanes; (c) NBS, CCl4; (d) KCN, 
H2O, THF; (e) HCl, methanol; (f) NaH, imidazole, THF; (g) KOH, H2O, THF; (h) NaH, 1,2,4-
triazole, THF.  
 
Analogue 32 was designed to probe the effect of introducing a hydroxyl group in the meta 
position of the “A” ring. The synthesis of 32 is outlined in Scheme 4. The phenolic hydroxyl 
group of 29 was first protected with a pivaloyl group. The product 30 reacted with 4,4'-
dihydroxybenzophenone under McMurry cross-coupling reaction conditions, followed by 
protection of the phenolic hydroxyl groups with MOMCl, to afford 31. Compound 31 underwent 
bromination with NBS, alkylation of imidazole, and removal of the pivaloyl group and MOM 
groups to afford 32 in good yield.  
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Scheme 4. Synthesis of Analogue 32a 
aReagents and conditions: (a) NaH, PvCl, THF; (b) 4,4'-dihydroxybenzophenone, Zn, TiCl4, 
THF; (c) NaH, MOMCl, THF; (d) NBS, CCl4; (e) NaH, imidazole, THF; (f) KOH, H2O, 
methanol; (g) HCl, methanol.  
To synthesize analogue 35 with a meta amino group in the “A” ring, 3-aminoacetophenone 
(33) was reacted with the di-protected 4,4'-dihydroxybenzophenone 22 under McMurry cross-
coupling reaction conditions, followed by protection of the amino group with a Boc group to 
afford 34 (in Scheme 5). Then, compound 34 underwent bromination with NBS, alkylation with 
imidazole and cleavage of the pivaloyl group and Boc group to provide 35 in good yield.  
Scheme 5. Synthesis of Analogue 35a 
aReagents and conditions: (a) 22, Zn, TiCl4, THF; (b) Boc2O, dioxanes; (c) NBS, CCl4; (d) NaH, 
imidazole, THF; (e) KOH, H2O, methanol; (f) HCl, methanol.  
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Biological Activities. The aromatase inhibitory activities and ER-α/ER-β binding affinities 
of the bisphenols are summarized in Table 1. Compound 11 with a nitrile side chain showed 
slightly improved aromatase inhibitory activity (IC50 12800 nM) when compared with compound 
7 (IC50 24900 nM), but it only displayed very weak binding affinity for both ER-α and ER-β. The 
imidazole compound 12 was the most potent aromatase inhibitor (IC50 4.77 nM) and it also 
retained high binding affinities with both ER-α (EC50 27.3 nM) and ER-β (EC50 40.9 nM). 
Compound 13 with the triazole side chain was also a good aromatase inhibitor (IC50 137 nM) but 
had weak ER binding affinity. Similar structure-activity relationships were also observed for 
compound series 17a-20a and series 17b-20b. The nitrile compounds (17a and 17b) are weak 
aromatase inhibitors (IC50 15200-17200 nM), and they showed no binding affinity for ER-α and 
ER-β. The triazole compounds (19a-b and 20a-b) are moderate aromatase inhibitors (IC50 2980-
14200 nM), but they only showed weak binding affinities for ER-α (EC50 ≥ 943 nM) and ER-β 
(EC50 ≥ 1080 nM). The imidazole compounds (18a and 18b) are very potent aromatase inhibitors 
(IC50 60.0-94.4 nM), and they also displayed good binding affinities for ER-α (IC50 85.2-97.8 
nM) and ER-β (IC50 56.3-73.6 nM). Compared with the "A" ring unsubstituted analogues 11-13, 
introducing a hydroxyl group in the para position of the "A" ring (analogues 17a-20a) 
unexpectedly resulted in moderate decreases in aromatase inhibitory activity or ER binding 
affinities. A comparison of series 17b-20b with series 17a-20a reveals that incorporating a 
fluorine atom ortho to the hydroxyl group produced minor effects on aromatase inhibitory 
activity and ER-α/ER-β binding affinity, except in the case of the two triazole systems it 
significantly decreased  ER-α/ER-β affinity. The introduction of an amino group in the para 
position of the "A" ring (analogues 25-28) either produced minor effects on aromatase inhibitory 
activity, or in the case of the nitriles 11 vs. 25, it increased the inhibitory activity dramatically 
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(IC50 12,800 vs. 36.3 nM). However, the para amino group is uniformly unfavorable for ER 
binding affinity. The imidazole 26 displayed much weaker binding affinities with ER-α (EC50 
1830 nM) and ER-β (EC50 296 nM) compared with compound 12, while compounds 25, 27 and 
28 all have weak binding affinities with ER. Rotating the "A" ring para hydroxyl group to the 
meta position (32 vs 18a) did not influence aromatase inhibitory activity, but it decreased the 
binding affinities with ER-α and ER-β significantly. Rotating the "A" ring para amino group to 
the meta position (35 vs 26) decreased both aromatase inhibitory activity and ER binding 
affinities.   
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Table 1. The Aromatase Inhibitory Activity and Estrogen Receptor Binding Affinities of 
Triphenylethylene Bisphenols a,b 
 
 
Cpd R1 R2 R3 
Aromatase 
(IC50, nM) 
ER-α 
(EC50, nM) 
ER-β 
(EC50, nM) 
7 -CH2CH3 -H -H 24900±1400 80% competition 307 ± 106 
11 -CH2CN -H -H 12800±2000 56% competition 49% competition 
12  -H -H 4.77 ± 0.38 27.3 ± 5.2 40.9 ± 12.1 
13  -H -H 137 ± 6 12% competition 33% competition 
17a -CH2CN -OH -H 15200±300 0% competition 3% competition 
18a  -OH -H 60.0 ± 4.1 97.8 ± 42.3 73.6 ± 29.9 
19a  -OH -H 3030 ± 150 45% competition 40% competition 
20a  -OH -H 12500±400 943 ± 285 1080 ± 100 
17b -CH2CN -OH -F 17200±2200 0% competition 0% competition 
18b  -OH -F 94.4 ± 3.5 85.2 ± 14.2 56.3 ± 17.8 
19b  -OH -F 2980 ± 50 2% competition 0% competition 
20b  -OH -F 14200±1100 0% competition 0% competition 
25 -CH2CN -NH2 -H 36.3 ± 0.8 0% competition 0% competition 
26  -NH2 -H 5.24 ± 0.41 1830 ± 910 296 ± 154 
27  -NH2 -H 104 ± 9 0% competition 2% competition 
28  -NH2 -H 17.7 ± 1.2 13% competition 36% competition 
32  -H -OH 60.4 ± 1.7 0% competition 29% competition 
35  -H -NH2 439 ± 16 60% competition 71% competition 
aThe values are mean values of at least three experiments. bPercent ER competition was 
determined at the concentration of 100 µM for each compound. EC50 values were determined 
only for compounds that displayed > 90% competition.  
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Transcriptional Activities in MCF-7 Human Breast Cancer Cells. To investigate the 
effects of ligand binding on ER-mediated transcriptional activities, the triphenylethylene 
bisphenols were tested for their abilities to antagonize β–estradiol (E2) in a functional assay. 
Four compounds (12, 18a, 18b and 26) were selected for this test because of their high binding 
affinities to both ER-α and ER-β. In this commonly used assay, the progesterone receptor (PGR) 
mRNA expression is used for assessing estrogenic or antiestrogenic activity in MCF-7 human 
breast cancer cells.32 As shown in Figure 4, E2 (10 nM) was able to significantly increase the 
PGR mRNA expression compared to the control, which contained only 0.1% methanol (vehicle). 
The PGR mRNA expression level with 10 nM E2 stimulation alone was set as 100%, and the 
antiestrogenic effects of the compounds was monitored by the reduction of -stimulated mRNA 
levels. Endoxifen (positive control) can antagonize the PGR mRNA expression in the presence 
of 10 nM E2 to 10%, which is consistent with the published result.32 (E,Z)-Norendoxifen can 
also antagonize the stimulatory effects of E2 as PGR mRNA expression level was reduced to 33% 
as we previously reported.25 All of the tested triphenylethylene bisphenol analogues (12, 18a, 
18b and 26) were able to antagonize the ER-stimulated PGR mRNA expression to the levels of 
26-31%, regardless of their different binding affinities with estrogen receptors. The 
antiestrogenic effects of the tested compounds as monitored by the reduction of estradiol-
stimulated mRNA levels were weaker than endoxifen, but very similar to (E,Z)-norendoxifen. 
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Figure 4. The abilities of compound 12, 18a, 18b and 26 (1 µM) to antagonize β-estradiol (E2, 
10 nM)-stimulated progesterone receptor (PGR) mRNA expression in MCF-7 cells.  
Molecular Modeling. Molecular docking studies were performed in order to investigate the 
possible binding mode of the triphenylethylene bisphenol analogues with aromatase and ER-α. 
Compound 12 was docked into the active site of aromatase (PDB code: 3s79)33 with GOLD 3.0. 
The high potency of 12 compared with 7 (> 5000 fold improvement in aromatase inhibitory 
activity) indicates imidazole-iron bonding. Therefore, a distance constraint (1.5-3.5 Å) was 
imposed between the imidazole nitrogen and iron during docking. The best docking pose of 12 
(shown in Figure 5a) was overlapped with the hypothetical binding mode of E-norendoxifen (E-
5) that was previously reported (please see Supporting Information for more detailed molecular
modeling results, including stereoviews, hydrogen bond angles, and distances calculated between 
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hydrogens and hydrogen bond acceptors).24 The binding mode of 12 is in general very similar to 
that of E-norendoxifen, a result that is not surprising since the imidazole fragment was installed 
in 12 in a location for iron binding based on the structure calculated for the E-norendoxifen-
aromatase complex. The imidazole group faces toward the heme and coordinates with the iron. 
One of the phenolic hydroxy groups forms a hydrogen bond with the backbone carbonyl group 
of Leu372, which is similar to E-norendoxifen binding. A notable difference between 12 and E-
norendoxifen can be observed in their interaction with Ser478 and Asp309. For E-norendoxifen, 
a hydrogen bond was observed between the ether oxygen and the side chain hydroxyl group 
Ser478. For compound 12, because of the size of the imidazole group the whole molecule moves 
"up" (further away from the heme) when compared with E-norendoxifen. Due to this move, the 
other phenolic hydroxy group moves away from Ser478 and approaches Asp309 with the 
formation of a hydrogen bond with the backbone carbonyl group of Asp309.  
To explore the binding mode with ER-α, compound 12 was docked into the active site of 
ER-α (PDB code: 3ert)34 with GOLD 3.0. The best docking pose of 12 (shown in Figure 5b) was 
overlapped with the published hypothetical binding mode of Z-norendoxifen (Z-5).  According to 
the docking results, the binding mode of 12 is nearly identical to that of Z-norendoxifen. The 
imidazole group is situated in the ethyl binding pocket surround by Met421, Met388 and 
Leu428. One of the phenolic hydroxy groups forms bifurcated hydrogen bonds with Arg394 and 
Glu353. The other phenolic hydroxy group projects toward the outside of the ligand binding 
pocket and forms a hydrogen bond with Thr347.  
20 
Figure 5. (a) The hypothetical binding mode of 12 (green) in the active site of aromatase (PDB 
code: 3s79)33 overlapped with E-norendoxifen (pink). (b) The hypothetical binding mode of 12 
(green) in the active site of ER-α (PDB code: 3ert)34 overlapped with and Z-norendoxifen (pink).  
Our previous testing results showed that the aminoethoxyl side chain of (E,Z)-norendoxifen 
(5) is favorable for aromatase inhibitory activity (>240 fold increase compared with 7, Figure 
6).24 In this report, the imidazole group of compound 12 is also demonstrated to be optimal for 
aromatase inhibitory activity (>5000 fold increase compared with 7). Unfortunately, combining 
the aminoethoxyl side chain and imidazole group in one molecule (compound 36) did not result 
in a more potent aromatase inhibitor than 12.26 The failure of combining optimal substitutions to 
afford the most potent compound can be attributed to the hypothetical imidazole-induced binding 
mode movement as noted for compound 12. The hypothetical binding mode of compound 36 
overlapped with the hypothetical binding mode of E-norendoxifen (E-5) is shown in Figure 6. 
Similar to compound 12, the imidazole nitrogen of 36 coordinates with the iron. Because of the 
size of the imidazole group, the whole molecule 36 also moves "up" (further away from the 
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heme) when compared with E-norendoxifen. This movement pushes the ether oxygen away from 
Ser478 (distance 3.7 Å vs 3.3 Å of E-norendoxifen) and weakens the hydrogen bond between the 
ether oxygen and the side chain of Ser478. This movement also pushes the aminoethoxy side 
chain away from Asp309, resulting in the loss of the salt bridge interaction (between the 
protonated amino group and the carboxyl group of Asp309) and hydrogen bond (between the 
protonated amino group and the backbone carbonyl group of Asp309). Therefore, the 
aminoethoxy side chain of compound 36 cannot contribute positively to the aromatase inhibitory 
activity.  
Figure 6. The hypothetical binding mode of compound 36 (cyan) in the active site of aromatase 
(PDB code: 3s79)33 overlapped with E-norendoxifen (pink), and the comparison of aromatase 
inhibitory activities of compound 7, 5, 12 and 36.  
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Conclusion 
A series of triphenylethylene bisphenol analogues were designed and synthesized by 
eliminating the aminoethoxy side chain of (E,Z)-norendoxifen. The biological testing results 
showed that an imidazole group in the location of the ethyl group was optimal for both aromatase 
inhibitory activity and ER binding affinities. The imidazole compounds 12, 18a, 18b, and 26 
displayed superior aromatase inhibitory activity compared with (E,Z)-norendoxifen, while 12 
also showed ER binding affinities comparable with (E,Z)-norendoxifen and 18a and 18b were 
slightly less active. These four imidazoles also act as antagonists in the ER transcriptional assays 
in MCF-7 breast cancer cells with activity similar to (E,Z)-norendoxifen. The possible binding 
modes of the most potent compound 12 with aromatase and ER-α were also investigated by 
molecular modeling and the results were used to rationalize the observed activity trends. Since 
these triphenylethylene bisphenol analogues have no possibility for the E/Z isomerization 
problems encountered with the norendoxifen analogues that were previously published, they 
introduce a superior class of compounds that can be developed toward the goal of obtaining 
therapeutically useful dual AI/SERM agents.  Any future biological work with these compounds 
should provide a detailed profile of their agonistic and antagonistic activities in various organs 
and tissues in animal models.  The facts that compound 12, along with 18a and 18b, have high 
binding affinity to ER-α and ER-β and are analogues of the SERM tamoxifen argue in favor of 
the possibility of them being estrogen antagonists in breast tissue and estrogenic agonists in other 
tissues. 
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Experimental Section 
General. Melting points were determined using capillary tubes with a Mel-Temp 
apparatus and are uncorrected. The nuclear magnetic resonance (1H and 13C NMR) spectra were 
recorded using a Bruker ARX300 spectrometer (300 MHz) with a QNP probe or a Bruker DRX-
2 spectrometer (500 MHz) with a BBO probe. High-resolution mass spectra were recorded on a 
double-focusing sector mass spectrometer with magnetic and electrostatic mass analyzers. The 
purities of biologically important compounds are determined by HPLC or elemental analyses. 
For elemental analyses, the observed percentages differ less than 0.40% from the calculated 
values. For HPLC, the major peak accounted for ≥95% of the combined total peak area when 
monitored by a UV detector at 254 nm. The HPLC analyses were performed on a Waters 1525 
binary HPLC pump/Waters 2487 dual λ absorbance detector system using a 5 µm C18 reversed 
phase column. The cytochrome P450 (CYP) inhibitor screening kit for aromatase (CYP19) was 
purchased from BD Biosciences (San Jose, CA). Estrogen receptor α and β competitor assay kits 
were purchased from Invitrogen (Carlsbad, CA).  
General Procedure for the McMurry Cross-Coupling Reaction. Zinc powder (653 mg, 
10 mmol) was suspended in dry THF (8 mL), the mixture was cooled to 0 oC, and then TiCl4 
(0.55 mL, 5 mmol) was added dropwise under argon. When the addition was complete, the 
mixture was warmed to room temperature and then heated at reflux for 2 h. After cooling down, 
a solution of the corresponding benzophenone (1 mmol) and ketone (3 mmol) in dry THF (8 mL) 
was added, and the mixture was heated at reflux in the dark for 3 h. After being cooled to room 
temperature, THF was evaporated. The residue was dissolved in saturated NH4Cl aqueous 
solution (20 mL) and extracted with ethyl acetate (20 mL X 4). The organic layers were 
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combined, dried over Na2SO4, concentrated in vacuo and further purified by silica gel column 
chromatography to provide the McMurry cross-coupling product.  
4-(1,1-Bis(4-hydroxyphenyl)prop-1-en-2-yl)phenyl Pivalate (15a). A suspension of 14a 
(678 mg, 4.98 mmol) and NaH (206 mg, 95%, 8.15 mmol) in dry THF (5 mL) was stirred under 
argon for 10 min, and then pivaloyl chloride (0.90 mL, 7.31 mmol) was added. The solution was 
stirred at room temperature for 3 h and quenched with water (2 mL). The solvent was evaporated, 
and the residue was dissolved with water (15 mL) and extracted with ethyl acetate (15 mL X 4). 
The organic layers were combined, dried over Na2SO4, and concentrated. The concentrated 
product was reacted with 4,4'-dihydroxylbenzophenone (1.98 g, 9.24 mmol) according to the 
general McMurry cross coupling reaction procedure. The product was purified by silica gel 
column chromatography (2:1 hexanes-ethyl acetate) to afford the product 15a as a white solid 
(1.55 g, 77%): mp 138-140 oC. 1H NMR (300 MHz, methanol-d4 and CDCl3) δ 7.11-7.08 (m, 2 
H), 7.03-7.00 (m, 2 H), 6.80-6.74 (m, 4 H), 6.69-6.66 (m, 2 H), 6.48-6.45 (m, 2 H), 2.07 (s, 3 H), 
1.29 (s, 9 H); 13C NMR (75 MHz, methanol-d4 and CDCl3) δ 179.3, 156.7, 156.0, 150.1, 143.7, 
140.7, 136.6, 136.3, 134.0, 133.5, 132.6, 131.7, 122.1, 116.1, 115.6, 40.4, 28.3, 24.5; ESIMS m/z 
(relative intensity) 425 (MNa+, 100); HRESIMS m/z calcd for C26H27O4 (MH+) 403.1909, found 
403.1916. 
4-(1,1-Bis(4-hydroxyphenyl)prop-1-en-2-yl)-2-fluorophenyl Pivalate (15b). A 
suspension of 14b (187 mg, 1.21 mmol) and NaH (70.7 mg, 95%, 2.42 mmol) in dry THF (5 
mL) was stirred at room temperature under argon. Pivaloyl chloride (0.22 mL, 1.8 mmol) was 
added dropwise. The mixture was stirred at room temperature for 3 h and quenched with water (2 
mL). The THF was evaporated, and the residue was dissolved with 20% K2CO3 solution (20 mL) 
and extracted with ethyl acetate (15 mL X 3). The organic layers were combined and dried over 
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Na2SO4 and concentrated. The residue was combined with 4 4'- dihydroxybenzophenone (0.80 g, 
3.73 mmol) and reacted according to the general McMurry cross-coupling reaction procedure. 
The product was further purified by silica gel column chromatography (7:3 hexanes-ethyl 
acetate) to afford the product 15b as yellow oil (348 mg, 68%). 1H NMR (300 MHz, CDCl3) δ 
7.07-7.04 (m, 2 H), 7.04-6.84 (m, 3 H), 6.79-6.76 (m, 2 H), 6.74-6.71 (m, 2 H), 6.52-6.49 (m, 2 
H), 2.09 (s, 3 H), 1.35 (s, 9 H); EIMS m/z (relative intensity)  420 (M+, 16), 57 (100); negative 
ion HRESIMS m/z calcd for C26H24FO4 (M - H+)¯ 419.1659, found 419.1665. 
(2-(4-Aminophenyl)prop-1-ene-1,1-diyl)bis(4,1-phenylene) Bis(2,2-
dimethylpropanoate) (23). Zinc powder (1.12 g, 17.1 mmol) was suspended in dry THF (10 
mL) and the mixture was cooled to 0 oC. TiCl4 (0.8 mL, 7.2 mmol) was added dropwise under 
argon. When the addition was complete, the mixture was warmed to room temperature and then 
heated at reflux for 2 h. After cooling down, a solution of 2235 (501 mg, 1.31 mmol) and 21 (175 
mg, 1.29 mmol) in dry THF (10 mL) was added, and the mixture was heated at reflux in the dark 
for 3 h. After the reaction mixture was cooled to room temperature, THF was carefully 
evaporated. The residue was dissolved with saturated ammonium chloride aqueous solution (20 
mL) and extracted with ethyl acetate (20 mL X 4). The organic layers were combined, dried over 
Na2SO4, concentrated in vacuo and further purified by silica gel column chromatography, eluting 
with 3:1 dichloromethane-hexanes, followed by 2:1 hexanes-ethyl acetate, to afford the product 
23 as yellow solid (284 mg, 45%): mp 208-210 oC. 1H NMR (300 MHz, CDCl3) δ 7.23-7.20 (m, 
2 H), 7.05-7.02 (m, 2 H), 6.95-6.92 (m, 2 H), 6.91-6.88 (m, 2 H), 6.76-6.73 (m, 2 H), 6.51-6.48 
(m, 2 H), 2.10 (s, 3 H), 1.37 (s, 9 H), 1.31 (s, 9 H); 13C NMR (75 MHz, CDCl3) δ  177.1, 176.9, 
149.5, 148.8, 144.8, 141.1, 140.7, 136.2, 136.1, 133.6, 131.8, 131.1, 130.3, 121.0, 120.4, 114.6, 
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39.1, 39.0, 27.1, 27.0, 23.3; ESIMS m/z (relative intensity) 508 (MNa+, 100); HRESIMS m/z 
calcd for C31H36NO4 (MH+) 486.2645, found 486.2648.  
General Procedure for the Preparation of 10 and 16a-b. A solution of bisphenol (9 or 
15a-b, 0.502 mmol) and NaH (53.0 mg, 95%, 2.10 mmol) in dry THF (5 mL) was stirred under 
argon for 10 min, and then methyl chloromethyl ether (0.16 mL, 2.10 mmol) was added. The 
mixture was stirred at room temperature for 3 h and quenched with saturated aqueous NaHCO3 
solution (2 mL). The solvent was evaporated, and the residue was dissolved in saturated aqueous 
NaHCO3 solution (15 mL) and extracted with ethyl acetate (15 mL X 4). The organic layers were 
combined, dried over Na2SO4, and concentrated in vacuo to provide the crude product 10 or 16a-
b.  
4,4'-(2-Phenylprop-1-ene-1,1-diyl)bis((methoxymethoxy)benzene) (10). The crude 
product was purified by silica gel column chromatography (9:1 hexanes-ethyl acetate) to provide 
the pure product 10 as a colorless oil (69%). 1H NMR (300 MHz, CDCl3) δ 7.18-7.07 (m, 7 H), 
7.04-7.00 (m, 2 H), 6.82-6.79 (m, 2 H), 6.71-6.68 (m, 2 H), 5.21 (s, 2 H), 5.07 (s, 2 H), 3.52 (s, 3 
H), 3.43 (s, 3 H), 2.14 (s, 3 H); 13C NMR (75 MHz, CDCl3) δ 155.9, 155.2, 144.3, 138.2, 137.3, 
136.9, 134.7, 132.0, 131.2, 129.3, 127.9, 126.0, 115.7, 115.0, 94.4, 94.3, 56.0, 55.9, 23.4; ESIMS 
m/z (relative intensity) 413 (MNa+, 100); HRESIMS m/z calcd for C25H26O4Na (MNa+) 
413.1729, found 413.1731.  
4-(1,1-Bis(4-(methoxymethoxy)phenyl)prop-1-en-2-yl)phenyl Pivalate (16a). The 
crude product was purified by silica gel column chromatography (85:15 hexanes-ethyl acetate) to 
provide the pure product 16a as a colorless oil (81%). 1H NMR (300 MHz, CDCl3) δ 7.16-7.13 
(m, 4 H), 7.02-6.99 (m, 2 H), 6.88-6.85 (m, 2 H), 6.82-6.79 (m, 2 H), 6.73-6.69 (m, 2 H), 5.19 (s, 
2 H), 5.08 (s, 2 H), 3.51 (s, 3 H), 3.43 (s, 3 H), 2.12 (s, 3 H), 1.34 (s, 9 H); 13C NMR (75 MHz, 
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CDCl3) δ 177.0, 155.9, 155.3, 149.1, 141.6, 138.5, 137.2, 136.7, 133.8, 132.0, 131.1, 130.2, 
120.8, 115.7, 115.2, 94.4, 56.0, 39.0, 27.1, 23.4; ESIMS m/z (relative intensity) 513 (MNa+, 
100); HRESIMS m/z calcd for C30H34O6Na (MNa+) 513.2253, found 513.2272.  
4-(1,1-Bis(4-(methoxymethoxy)phenyl)prop-1-en-2-yl)-2-fluorophenyl Pivalate (16b). 
The crude product was purified by silica gel column chromatography (85:15 hexanes-ethyl 
acetate) to provide the product 16b as a colorless oil (194 mg, 49%). 1H NMR (300 MHz, 
CDCl3) δ 7.15-7.11 (m, 2 H), 7.02-6.99 (m, 2 H), 6.97-6.87 (m, 3 H), 6.82-6.79 (m, 2 H), 6.74-
6.71 (m, 2 H), 5.19 (s, 2 H), 5.08 (s, 2 H), 3.50 (s, 3 H), 3.43 (s, 3 H), 2.10 (s, 3 H), 1.36 (s, 9 H); 
MALDIMS m/z (relative intensity) 508 (M+, 80), 379 (100); HRESIMS m/z calcd for 
C30H33FO6Na (MNa+) 531.2159, found 531.2143.  
General Procedure for the Preparation of 11, 17a-b and 25. A solution of 10 or 16a-b 
or 24 (0.169 mmol) and N-bromosuccinimide (30.8 mg, 0.173 mmol) in CCl4 (5 mL) was heated 
at reflux under argon for 3 h. After cooling down, the solid was removed by filtration and the 
filtrate was concentrated in vacuo. The residue was dissolved in THF (4.5 mL) and a solution of 
KCN (46.2 mg, 0.709 mmol) in water (1.5 mL) was added. The mixture was stirred at room 
temperature overnight. The solvent was evaporated, and the residue was dissolved with water (10 
mL) and extracted with ethyl acetate (10 mL X 3). The organic layers were combined, dried over 
Na2SO4, and concentrated in vacuo. The residue was dissolved with methanol (4.5 mL) and 
concentrated HCl (1 mL) was added. The solution was stirred at room temperature overnight. 
The solvent was removed, and the residue was dissolved with water (10 mL), neutralized with 
NaHCO3, and extracted with ethyl acetate (10 mL X 3). The organic layers were combined, dried 
over Na2SO4, and concentrated in vacuo to provide the crude product 11 or 17a-b or 25.  
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4,4-Bis(4-hydroxyphenyl)-3-phenylbut-3-enenitrile (11). The crude product was 
purified by silica gel column chromatography (2:1 hexanes-ethyl acetate) to provide the pure 
product 11 as an orange solid (61.7 mg, 51%): mp 198-200 oC.  1H NMR (300 MHz, methanol-
d4 and CDCl3) δ 7.19-7.10 (m, 5 H), 7.09-7.05 (m, 2 H), 6.83-6.79 (m, 2 H), 6.69-6.65 (m, 2 H), 
6.47-6.43 (m, 2 H), 3.50 (s, 2 H); 13C NMR (75 MHz, methanol-d4 and CDCl3) δ 157.9, 157.0, 
145.9, 141.5, 134.7, 134.3, 133.3, 132.1, 130.9, 129.7, 128.5, 127.2, 120.0, 116.8, 115.8, 26.8; 
EIMS m/z (relative intensity) 327 (M+, 100); HREIMS m/z calcd for C22H17NO2 (M+) 327.1254, 
found 327.1264. Anal. Calcd for C22H17NO2·CH3OH: C, 76.86; H, 5.89; N, 3.90. Found: C, 
76.88; H, 5.57; N, 3.93.  
3,4,4-Tris(4-hydroxyphenyl)but-3-enenitrile (17a). The crude product 17a was purified 
by silica gel column chromatography (1:1 hexanes-ethyl acetate) to provide the pure product as 
red foam (83%). 1H NMR (300 MHz, methanol-d4) δ 7.07-7.00 (m, 4 H), 6.84-6.80 (m, 2 H), 
6.73-6.69 (m, 2 H), 6.66-6.62 (m, 2 H), 6.50-6.46 (m, 2 H), 3.53 (s, 2 H); 13C NMR (75 MHz, 
methanol-d4) δ 158.2, 157.6, 157.2, 144.5, 135.1, 134.8, 133.1, 132.7, 132.0, 131.8, 127.7, 120.1, 
116.4, 116.2, 115.4, 25.8; ESIMS m/z (relative intensity) 366 (MNa+, 100); HRESIMS m/z calcd 
for C22H17NO3Na (MNa+) 366.1106, found 366.1120. HPLC purity 99.8% (C-18 reverse phase, 
methanol-H2O, 90:10).  
3-(3-Fluoro-4-hydroxyphenyl)-4,4-bis(4-hydroxyphenyl)but-3-enenitrile (17b). The 
crude product was purified by silica gel column chromatography (1:1 hexanes-ethyl acetate) to 
provide the pure product 17b as white solid (70%): mp 180-183 oC. 1H NMR (300 MHz, 
methanol-d4) δ 7.07-7.04 (m, 2 H), 6.91-6.87 (m, 1 H), 6.84-6.79 (m, 3 H), 6.78-6.75 (m, 1 H), 
6.73-6.70 (m, 2 H), 6.53-6.49 (m, 2 H), 3.55 (s, 2 H); EIMS m/z (relative intensity) 361 (M+, 
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100); negative ion HRESIMS m/z calcd for C22H15FNO3 (M - H+)¯ 360.1036, found 360.1033. 
HPLC purity 99.3% (C-18 reverse phase, methanol-H2O, 90:10).  
3-(4-Aminophenyl)-4,4-bis(4-hydroxyphenyl)but-3-enenitrile (25). The crude product 
25 was purified by silica gel column chromatography (1:1 hexanes-ethyl acetate) to provide the 
pure product 25 as white yellow solid (70%): mp 235-238 oC.  1H NMR (300 MHz, methanol-d4) 
δ 7.06-7.03 (m, 2 H), 6.96-6.93 (m, 2 H), 6.82-6.79 (m, 2 H), 6.72-6.69 (m, 2 H), 6.59-6.56 (m, 2 
H), 6.47-6.44 (m, 2 H), 3.52 (s, 2 H); 13C NMR (75 MHz, methanol-d4) δ 158.1, 157.1, 147.9, 
143.9, 135.3, 135.0, 133.1, 131.8, 131.6, 131.1, 128.0, 120.2, 116.4, 116.3, 115.3, 25.7; EIMS 
m/z (relative intensity) 342 (M+, 100); HRESIMS m/z calcd for C22H19N2O2 (MH+) 343.1447, 
found 343.1446. HPLC purity 97.8% (C-18 reverse phase, methanol-H2O, 90:10).  
General Procedure for the Preparation of 12 and 13. A solution of 10 (186 mg, 0.476 
mmol) and N-bromosuccinimide (81.7 mg, 0.459 mmol) in CCl4 (5 mL) was heated at reflux 
under argon for 3 h. After cooling down, the solid was removed by filtration and the filtrate was 
concentrated in vacuo. The residue was dissolved in dry THF (8 mL) and the solution was added 
to a solution of imidazole or 1,2,4-triazole (1.07 mmol) and NaH (30.1 mg, 1.25 mmol) in THF 
(4 mL) at 0 oC. The mixture was warmed to room temperature and stirred under argon overnight. 
The reaction was quenched with saturated NH4Cl aqueous solution (1 mL). The solvent was 
evaporated, and the residue was dissolved with saturated NH4Cl aqueous solution (25 mL) and 
extracted with ethyl acetate (25 mL X 4). The organic layers were combined, dried over Na2SO4, 
and concentrated in vacuo. The residue was dissolved with methanol (5 mL), concentrated HCl 
(0.4 mL), and heated at reflux for 0.5 h. The solvent was removed, and the residue was 
neutralized with saturated NaHCO3 solution (15 mL) and extracted with ethyl acetate (15 mL X 
4). The organic layers were combined, dried over Na2SO4, concentrated in vacuo and further 
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purified by silica gel column chromatography (95:5 dichloromethane-methanol) to provide the 
product 12 or 13.  
4,4'-(3-(1H-Imidazol-1-yl)-2-phenylprop-1-ene-1,1-diyl)diphenol (12). The purified 
product was dissolved in DMSO (1 mL) and then diluted with water (10 mL). The solid was 
collected by filtration and dried in vacuo to provide the product 12 as a yellow solid (150 mg, 
89%): mp 225-227 oC.  1H NMR (300 MHz, DMSO-d6) δ 7.41 (s, 1 H), 7.10-6.99 (m, 8 H), 6.79-
6.76 (m, 3 H), 6.69-6.66 (m, 2 H), 6.44-6.41 (m, 2 H), 4.89 (s, 2 H); 13C NMR (75 MHz, DMSO-
d6) δ 157.6, 156.8, 144.8, 140.8, 133.6, 132.7, 132.3, 131.0, 130.4, 128.8, 127.4, 119.9, 116.2, 
115.3, 51.1; ESIMS m/z (relative intensity) 369 (MH+, 33), 301 (100); HRESIMS m/z calcd for 
C24H20N2O2Na (MNa+) 391.1422, found 391.1414. Anal. Calcd for C24H20N2O2·1.3 H2O: C, 
73.56; H, 5.81; N, 7.15. Found: C, 73.47; H, 5.83; N, 6.90.  
4,4'-(2-Phenyl-3-(1H-1,2,4-triazol-1-yl)prop-1-ene-1,1-diyl)diphenol (13). Yellow solid 
(54 mg, 54%): mp 143-145 oC.  1H NMR (300 MHz, methanol-d4 and CDCl3) δ 7.98 (s, 1 H), 
7.90 (s, 1 H), 7.19-7.15 (m, 2 H), 7.08-7.02 (m, 5 H), 6.80-6.77 (m, 2 H), 6.73-6.69 (m, 2 H), 
6.46-6.43 (m, 2 H), 5.20 (s, 2 H); 13C NMR (75 MHz, methanol-d4 and CDCl3) δ 158.0, 157.1, 
147.3, 140.9, 134.5, 133.4, 132.1, 130.8, 129.7, 128.2, 116.6, 115.7, 56.0; EIMS m/z (relative 
intensity) 369 (M+, 53), 300 (100); HREIMS m/z calcd for C23H19N3O2 (M+) 369.1472, found 
369.1484. Anal. Calcd for C23H19N3O2·1.6 CH3OH: C, 70.23; H, 6.09; N, 9.99. Found: C, 70.48; 
H, 5.70; N, 9.59.   
General Procedure for the Preparation of 18a-b and 26. A solution of 16a-b or 24 
(0.127 mmol) and N-bromosuccinimide (24.8 mg, 0.139 mmol) in CCl4 (5 mL) was heated at 
reflux under argon for 3 h. After cooling down, the solid was removed by filtration and the 
filtrate was concentrated in vacuo. The residue was dissolved in dry THF (5 mL) and the solution 
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was added to a solution of imidazole (35.4 mg, 0.52 mmol) and NaH (27.1 mg, 95%, 1.07 mmol) 
in THF (3 mL). The mixture was stirred at room temperature overnight. The reaction was 
quenched with saturated NH4Cl aqueous solution (1 mL). The solvent was evaporated, and the 
residue was dissolved with saturated NH4Cl aqueous solution (10 mL) and extracted with ethyl 
acetate (10 mL X 3). The organic layers were combined, dried over Na2SO4 and concentrated in 
vacuo. The product was dissolved in THF (2.5 mL) and 2 N KOH solution (2.5 mL) was added. 
The mixture was stirred at room temperature overnight. The solvent was evaporated, and the 
residue was dissolved with saturated NH4Cl aqueous solution (15 mL) and extracted with ethyl 
acetate (10 mL X 3). The organic layers were combined, dried over Na2SO4, concentrated in 
vacuo and further purified by silica gel column chromatography (95:5 dichloromethane-
methanol). The purified product was dissolved with methanol (4.5 mL) and concentrated HCl (1 
mL) was added. The mixture was stirred at room temperature overnight. The solvent was 
evaporated, and the residue was dissolved with water (10 mL), neutralized with NaHCO3, and 
extracted with ethyl acetate (10 mL X 3). The organic layers were combined, dried over Na2SO4, 
concentrated in vacuo and further purified by silica gel column chromatography (9:1 
dichloromethane-methanol) to provide the product 18a-b or 26.  
4,4',4''-(3-(1H-Imidazol-1-yl)prop-1-ene-1,1,2-triyl)triphenol (18a). Red glass (58%). 
1H NMR (300 MHz, methanol-d4) δ 7.35 (s, 1 H), 7.06-7.03 (m, 2 H), 6.91 (s, 1 H), 6.88-6.79 
(m, 5 H), 6.77-6.73 (m, 2 H), 6.58-6.54 (m, 2 H), 6.49-6.45 (m, 2 H), 4.88 (s, 2 H); 13C NMR (75 
MHz, methanol-d4) δ 158.0, 157.3, 157.1, 145.2, 138.3, 134.9, 133.0, 132.4, 132.1, 131.7, 128.6, 
120.5, 116.4, 116.1, 115.4, 52.2; negative ion ESIMS m/z (relative intensity) 383 [(M - H+)¯, 8], 
315 (100); negative ion HREIMS m/z calcd for C24H19N2O3 (M - H+)¯ 383.1396, found 383.1398. 
HPLC purity 97.6% (C-18 reverse phase, methanol-H2O, 90:10).  
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4,4'-(2-(3-Fluoro-4-hydroxyphenyl)-3-(1H-imidazol-1-yl)prop-1-ene-1,1-diyl)diphenol 
(18b). Orange foam (49%). 1H NMR (300 MHz, methanol-d4) δ 7.41 (s, 1 H), 7.08-7.05 (m, 2 
H), 6.97 (s, 1 H), 6.85 (s, 1 H), 6.82-6.79 (s, 2 H), 6.77-6.74 (m, 2 H), 6.73-6.65 (m, 3 H), 6.51-
6.48 (m, 2 H), 4.92 (s, 2 H); ESIMS m/z (relative intensity) 403 (MH+, 13), 335 (100); 
HRESIMS m/z calcd for C24H20FN2O3 (MH+) 403.1458, found 403.1459. HPLC purity 98.9% 
(C-18 reverse phase, methanol-H2O, 90:10).  
4,4'-(2-(4-Aminophenyl)-3-(1H-imidazol-1-yl)prop-1-ene-1,1-diyl)diphenol (26). 
Yellow foam (59%). 1H NMR (300 MHz, methanol-d4) δ 7.40 (s, 1 H), 7.05-7.01 (m, 2 H), 6.94 
(s, 1 H), 6.84-6.73 (m, 7 H), 6.52-6.49 (m, 2 H), 6.47-6.43 (m, 2 H), 4.90 (s, 2 H); 13C NMR (75 
MHz, methanol-d4) δ 158.0, 157.1, 147.6, 144.8, 138.2, 135.1, 133.2, 133.0, 131.7, 130.8, 128.3, 
120.6, 116.3, 115.3, 52.2; ESIMS m/z (relative intensity) 384 (MH+, 18), 316 (100); HRESIMS 
m/z calcd for C24H22N3O2 (MH+) 384.1712, found 384.1725. HPLC purity 99.4% (C-18 reverse 
phase, methanol-H2O, 90:10), 99.8% (C-18 reverse phase, methanol-H2O, 85:15).  
General Procedure for the Preparation of 19a-b, 20a-b, 27 and 28. A solution of 16a-b 
or 24 (0.201 mmol) and N-bromosuccinimide (35.8 mg, 0.201 mmol) in CCl4 (5 mL) was heated 
at reflux under argon for 3 h. After cooling down, the solid was removed by filtration and the 
filtrate was concentrated in vacuo. The residue was dissolved in dry THF (6 mL) and the solution 
was added to a solution of 1,2,4-triazole (42.6 mg, 0.62 mmol) and NaH (32 mg, 95%, 1.27 
mmol) in THF (3 mL). The mixture was stirred at room temperature overnight. The reaction was 
quenched with saturated NH4Cl aqueous solution (1 mL). The solvent was evaporated, and the 
residue was dissolved in saturated ammonium chloride aqueous solution (10 mL) and extracted 
with ethyl acetate (10 mL X 3). The organic layers were combined, dried over Na2SO4, and 
concentrated in vacuo. The product was dissolved in THF (2.5 mL) and 2 N KOH solution (2.5 
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mL) was added. The mixture was stirred at room temperature overnight. The solvent was 
evaporated, and the residue was dissolved with saturated aqueous ammonium chloride solution 
(15 mL) and extracted with ethyl acetate (10 mL X 3). The organic layers were combined, dried 
over Na2SO4, concentrated in vacuo and further purified by silica gel column chromatography 
(95:5 dichloromethane-methanol). The purified product was dissolved in methanol (4.5 mL) and 
concentrated HCl (1 mL) was added. The mixture was stirred at room temperature overnight. 
The solvent was evaporated, and the residue was dissolved in water (10 mL), neutralized with 
NaHCO3, and extracted with ethyl acetate (10 mL X 3). The organic layers were combined, dried 
over Na2SO4, concentrated in vacuo and further purified by silica gel column chromatography 
(9:1 dichloromethane-methanol) to first provide 19a-b or 27 and then 20a-b or 28.  
4,4',4''-(3-(1H-1,2,4-Triazol-1-yl)prop-1-ene-1,1,2-triyl)triphenol (19a). Yellow oil 
(93.1 mg, 60%). 1H NMR (300 MHz, methanol-d4) δ 8.00 (s, 1 H), 7.87 (s, 1 H), 7.28-7.25 (m, 2 
H), 6.90-6.87 (m, 2 H), 6.81-6.74 (m, 4 H), 6.55-6.52 (m, 2 H), 6.49-6.46 (m, 2 H), 5.18 (s, 2 H); 
13C NMR (75 MHz, methanol-d4) δ 158.0, 157.3, 157.1, 151.8, 145.3, 135.2, 134.8, 133.2, 132.2, 
132.1, 131.9, 116.2, 116.1, 115.4, 55.0; negative ion ESIMS m/z (relative intensity) 384 [(M - 
H+)¯ , 5], 315 (100); negative ion HREIMS m/z calcd for C23H18N3O3 [(M - H+)¯] 384.1348, 
found 384.1353. HPLC purity 98.8% (C-18 reverse phase, methanol-H2O, 90:10).  
4,4',4''-(3-(4H-1,2,4-Triazol-4-yl)prop-1-ene-1,1,2-triyl)triphenol (20a). Yellow oil 
(32.5 mg, 21%). 1H NMR (300 MHz, methanol-d4) δ 8.23 (s, 2 H), 7.08-7.05 (m, 2 H), 6.95-6.92 
(m, 2 H), 6.83-6.80 (m, 2 H), 6.78-6.75 (m, 2 H), 6.60-6.57 (m, 2 H), 6.48-6.45 (m, 2 H), 5.03 (s, 
2 H); 13C NMR (75 MHz, methanol-d4) δ 158.2, 157.7, 157.4, 146.0, 144.5, 134.7, 134.5, 133.0, 
132.1, 131.8, 131.5, 116.5, 116.4, 115.4, 50.8; negative ion ESIMS m/z (relative intensity) 384 
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[(M - H+)¯ , 3], 315 (100); negative ion HREIMS m/z calcd for C23H18N3O3 (M - H+)¯ 384.1348, 
found 384.1359. HPLC purity 96.1% (C-18 reverse phase, methanol-H2O, 90:10).  
4,4'-(2-(3-Fluoro-4-hydroxyphenyl)-3-(1H-1,2,4-triazol-1-yl)prop-1-ene-1,1-
diyl)diphenol (19b). Orange foam (37%). 1H NMR (300 MHz, methanol-d4) δ 8.07 (s, 1 H), 
7.90 (s, 1 H), 7.29-7.26 (s, 2 H), 6.83-6.61 (m, 7 H), 6.52-6.47 (m, 2 H), 5.20 (s, 2 H); ESIMS 
m/z (relative intensity) 426 (MNa+, 100); HRESIMS m/z calcd for C23H18FN3O3Na (MNa+) 
426.1230, found 426.1243. HPLC purity 99.6% (C-18 reverse phase, methanol-H2O, 90:10).  
4,4'-(2-(3-Fluoro-4-hydroxyphenyl)-3-(4H-1,2,4-triazol-4-yl)prop-1-ene-1,1-
diyl)diphenol (20b). Yellow foam (21%). 1H NMR (300 MHz, methanol-d4) δ 8.31 (s, 2 H), 
7.11-7.06 (m, 2 H), 6.86-6.66 (m, 7 H), 6.53-6.49 (m, 2 H), 5.06 (s, 2 H); ESIMS m/z (relative 
intensity) 426 (MNa+, 100); HRESIMS m/z calcd for C23H18FN3O3Na (MNa+) 426.1230, found 
426.1244. HPLC purity 98.0% (C-18 reverse phase, methanol-H2O, 90:10).  
4,4'-(2-(4-Aminophenyl)-3-(1H-1,2,4-triazol-1-yl)prop-1-ene-1,1-diyl)diphenol (27). 
Orange foam (24%). 1H NMR (300 MHz, methanol-d4) δ 8.02 (s, 1 H), 7.87 (s, 1 H), 7.26-7.23 
(m, 2 H), 6.85-6.82 (m, 2 H), 6.79-6.73 (m, 4 H), 6.50-6.43 (m, 4 H), 5.19 (s, 2 H); 13C NMR (75 
MHz, methanol-d4) δ 158.0, 157.1, 151.7, 147.5, 145.2, 144.8, 135.4, 135.0, 133.1, 132.1, 131.7, 
130.3, 116.3, 116.1, 115.3, 54.9; ESIMS m/z (relative intensity) 407 (MNa+, 100); HRESIMS 
m/z calcd for C23H20N4O2Na (MNa+) 407.1484, found 407.1490. HPLC purity 97.6% (C-18 
reverse phase, methanol-H2O, 90:10).  
4,4'-(2-(4-Aminophenyl)-3-(4H-1,2,4-triazol-4-yl)prop-1-ene-1,1-diyl)diphenol (28). 
Yellow foam (20%). 1H NMR (300 MHz, methanol-d4) δ 8.24 (s, 2 H), 7.06-7.03 (m, 2 H), 6.89-
6.86 (m, 2 H), 6.83-6.80 (m, 2 H), 6.79-6.76 (m, 2 H), 6.54-6.51 (m, 2 H), 6.47-6.44 (m, 2 H), 
5.03 (s, 2 H); 13C NMR (75 MHz, methanol-d4) δ 158.2, 157.3, 148.0, 145.4, 144.5, 134.9, 134.7, 
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133.0, 132.0, 131.7, 131.5, 129.7, 116.5, 116.4, 115.3, 50.8; ESIMS m/z (relative intensity) 407 
(MNa+, 100); HRESIMS m/z calcd for C23H20N4O2Na (MNa+) 407.1484, found 407.1498. HPLC 
purity 99.2% (C-18 reverse phase, methanol-H2O, 90:10).  
(2-(4-((tert-Butoxycarbonyl)amino)phenyl)prop-1-ene-1,1-diyl)bis(4,1-phenylene) 
Bis(2,2-dimethylpropanoate) (24). A solution of 23 (284 mg, 0.585 mmol) and Boc2O (207 mg, 
0.948 mmol) in dry dioxane (10 mL) was heated at reflux under argon for 5 h. After cooling 
down, the solvent was evaporated, and the residue was dissolved with 10% K2CO3 solution (20 
mL) and exacted with ethyl acetate (20 mL X 3). The organic layers were combined, dried over 
Na2SO4, concentrated and further purified by silica gel column chromatography (85:15 hexanes-
ethyl acetate) to provide 24 as white solid (274 mg, 80%): mp 187-190 oC. 1H NMR (300 MHz, 
CDCl3) δ 7.23-7.20 (m, 2 H), 7.18-7.15 (m, 2 H), 7.06-7.02 (m, 4 H), 6.89-6.86 (m, 2 H), 6.75-
6.72 (m, 2 H), 2.10 (s, 3 H), 1.50 (s, 9 H), 1.36 (s, 9 H), 1.30 (s, 9 H); 13C NMR (75 MHz, 
CDCl3) δ 177.0, 176.9, 149.6, 149.0, 146.7, 140.7, 140.2, 138.1, 137.2, 136.6, 135.7, 131.8, 
131.0, 129.8, 121.1, 120.4, 117.8, 80.4, 39.1, 39.0, 27.4, 27.1, 27.0, 23.3; EIMS m/z (relative 
intensity) 585 (M+, 0.6), 57 (100); HRESIMS m/z calcd for C36H43NO6Na (MNa+) 608.2988, 
found 608.3009.  
3-Acetylphenyl Pivalate (30).36 A solution of compound 29 (421 mg, 3.09 mmol) in dry 
THF (7 mL) was stirred under argon. NaH (111 mg, 95%, 4.39 mmol) was added portionwise. 
The solution was stirred for 30 min and then trimethylacetyl chloride (0.6 mL, 4.87 mmol) was 
added dropwise. After stirring for 2 h, the reaction was quenched with H2O (2 mL) and the 
solvent was evaporated. The residue was dissolved with H2O (20 mL) and extracted with ethyl 
acetate (3×10 mL). The organic layers were combined, dried over Na2SO4, concentrated in 
vacuo and further purified by silica gel chromatography (4:1 hexanes-ethyl acetate) to provide 30 
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as pale yellow oil (541 mg, 95%). 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 7.7 Hz, 1 H), 7.59 
(s, 1 H), 7.40 (t, J = 7.9 Hz, 1 H), 7.21 (d, J = 8.1 Hz, 1 H), 2.53 (s, 3 H), 1.32 (s, 9 H).  
3-(1,1-Bis(4-(methoxymethoxy)phenyl)prop-1-en-2-yl)phenyl Pivalate (31). The 
acetophenone 30 (1.47 g, 6.67 mmol) and 4,4'-dihydroxylbenzophenone (0.953 g, 4.4 mmol) 
were reacted according to the general McMurry cross-coupling reaction procedure. The product 
was purified by silica gel column chromatography (2:1 hexanes-ethyl acetate) to provide impure 
bisphenol intermediate which was dissolved in dry THF (20 mL) and treated with NaH (0.231 g, 
95%, 9.14 mmol). The mixture was stirred 30 min under argon, and then chloromethyl methyl 
ether (2.0 mL, 9.0 mmol) was added dropwise. After stirring 3 h, the reaction was quenched with 
saturated NaHCO3 (10 mL) and the solvent was evaporated. The organic products were extracted 
from the aqueous phase using ethyl acetate (3×15 mL). The organic layers were combined, dried 
over Na2SO4, concentrated and purified by silica gel column chromatography, eluting with 6:1 
hexanes-ethyl acetate to provide product 31 as pale yellow oil (0.912 g, 43%). 1H NMR (300 
MHz, CDCl3) δ 7.19-7.09 (m, 3 H), 7.06-7.00 (m, 2 H), 6.95 (dt, J = 7.7, 1.3 Hz, 1 H), 6.89 (t, J 
= 2.0 Hz, 1 H), 6.86-6.78 (m, 3 H), 6.76-6.71 (m, 2 H), 5.20 (s, 2 H), 5.08 (s, 2 H), 3.51 (s, 3 H), 
3.43 (s, 3 H), 2.15 (s, 3 H), 1.34 (s, 9 H); 13C NMR (75 MHz, CDCl3) δ 176.92, 155.92, 155.45, 
150.75, 145.63, 138.87, 137.06, 136.52, 133.56, 131.88, 131.09, 128.66, 126.78, 122.19, 119.07, 
115.71, 115.18, 94.40, 55.91, 38.97, 27.08, 23.17; ESIMS m/z (MNa+) 513; HRESIMS m/z cacld 
for C30H34O6 (MNa+) 513.2253, found 513.2234.  
4,4'-(2-(3-Hydroxyphenyl)-3-(1H-imidazol-1-yl)prop-1-ene-1,1-diyl)diphenol (32). A 
solution of 31 (0.68 g, 1.39 mmol) and N-bromosuccinimide (247 mg, 1.39 mmol) in CCl4 (30 
mL) was heated at reflux under argon for 2 h. After cooling down, the solid was filtered off, and 
the solvent was evaporated. The residue was dissolved in dry THF (10 mL) and added to a 
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solution of NaH (67 mg, 95%, 2.78 mmol) and imidazole (143 mg, 2.1 mmol) in dry THF (10 
mL). The mixture was stirred at room temperature overnight. The reaction was then quenched 
with saturated NH4Cl (4 mL) solution and the solvent was evaporated.  The product was 
extracted from saturated NH4Cl (15 mL) solution using ethyl acetate (3×15 mL). The organic 
layers were combined, dried over Na2SO4 and concentrated. The product was dissolved in 
methanol (5 mL) and treated with 2 N KOH to bring the pH above 12. After the reaction mixture 
was stirred overnight, it was quenched with saturated NH4Cl (10 mL) solution and the solvents 
were evaporated. The product was extracted from saturated NH4Cl (10 mL) solution using ethyl 
acetate (4×10 mL). The organic layers were combined, dried over Na2SO4 and concentrated. The 
product was dissolved in methanol (10 mL) and treated with concentrated HCl (1 mL). After 
stirring overnight, the reaction was neutralized using NaHCO3 and methanol was evaporated. 
Saturated NH4Cl (10 mL) solution was added and the product was extracted using ethyl acetate 
(3×10 mL). The organic layers were combined, washed with brine, dried over Na2SO4, 
concentrated, and further purified using silica gel column chromatography, eluting with 10:1 
dichloromethane-methanol to provide 32 (103 mg, 21%) as white glass. 1H NMR (300 MHz, 
methanol-d4 ) δ 7.35 (s, 1 H), 7.09-7.04 (m, 2 H), 7.01-6.90 (m, 2 H), 6.86-6.74 (m, 5 H), 6.56 
(dd, J = 2.0, 1.1 Hz, 1 H), 6.52 (dq, J = 4.2, 1.6 Hz, 2 H), 6.49-6.43 (m, 2 H), 4.89 (s, 2 H); 13C 
NMR (75 MHz, methanol-d4) δ 160.80, 160.65, 159.84, 148.40, 145.46, 140.76, 137.12, 137.01, 
135.68, 135.39, 134.14, 132.82, 131.11, 124.67, 123.00, 120.24, 118.87, 117.84, 117.40, 54.78; 
ESIMS m/z (relative intensity) 385 (MH+, 16), 317 (100); HRESIMS m/z cacld for C24H20N2O3 
(MH+) 385.1552, found 385.1556. HPLC purity: 100% (C-18 reverse phase, methanol-H2O, 
90:10).   
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(2-(3-((tert-Butoxycarbonyl)amino)phenyl)prop-1-ene-1,1-diyl)bis(4,1-phenylene) 
Bis(2,2-dimethylpropanoate) (34). The acetophenone 33 (0.201 g, 1.49 mmol) and 
benzophenone 22 (0.682 g, 1.78 mmol) were reacted according to the general McMurry cross-
coupling reaction procedure. The product was purified by silica gel chromatography (4:1 
hexanes-ethyl acetate) to provide the impure intermediate, which was then treated with di-tert-
butyl dicarbonate (0.312 g, 1.43 mmol) in THF (20 mL). The reaction mixture stirred under 
argon for 36 h. The solvent was evaporated and the residue was purified by silica gel 
chromatography (4:1 hexanes-ethyl acetate) to provide 34 as cloudy oil (0.685 g, 79%). 1H NMR 
(300 MHz, CDCl3) δ 7.25-7.13 (m, 4 H), 7.11-7.02 (m, 3 H), 6.92-6.86 (m, 2 H), 6.78 (s, 1 H), 
6.76-6.71 (m, 2 H), 6.42 (brs, 1 H), 2.12 (s, 3 H), 1.51 (s, 9 H), 1.37 (s, 9 H), 1.30 (s, 9 H); 13C 
NMR (75 MHz, CDCl3) δ 177.01, 152.65, 149.69, 149.06, 144.51, 140.44, 139.98, 138.03, 
137.55, 136.06, 131.65, 130.96, 128.56, 124.21, 121.09, 120.40, 119.08, 116.68, 80.31, 39.06, 
28.31, 27.05, 23.42; HRESIMS m/z (relative intensity) calcd for C36H43NO6 (MNa+) 608.2988, 
found 608.2999.  
4,4'-(2-(3-Aminophenyl)-3-(1H-imidazol-1-yl)prop-1-ene-1,1-diyl)diphenol (35). A 
solution of 34 (0.341 g, 0.58 mmol) and N-bromosuccinimide (83 mg, 0.46 mmol) in CCl4 (30 
mL) was heated at reflux under argon for 2 h. After cooling down, the solid was filtered off, and 
the solvent was evaporated. The residue was dissolved in dry THF (10 mL) and added to a 
solution of NaH (16 mg, 95%, 0.63 mmol) and imidazole (39 mg, 0.58 mmol) in dry THF (15 
mL). The mixture was stirred at room temperature overnight. The reaction was then quenched 
with saturated NH4Cl (3 mL) solution and the solvent was evaporated. The residue was dissolved 
in saturated NH4Cl (10 mL) and the product was extracted using ethyl acetate (3×15 mL). The 
organic layers were combined, washed with brine (10 mL), dried over Na2SO4 and concentrated. 
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The product was dissolved in methanol-THF (7:3, 10 mL) and treated with 1 N KOH (2 mL). 
After the reaction mixture stirred 1 h, it was quenched with saturated NH4Cl (10 mL), and the 
solvent was evaporated. The product was extracted using ethyl acetate (3×15 mL), and the 
combined extract was dried over Na2SO4, concentrated, dissolved in methanol (8 mL), and the 
solution was treated with concentrated HCl (1.5 mL). After stirring 2 h at 50 oC, the reaction was 
neutralized using NaHCO3 and methanol was evaporated. Saturated NH4Cl (10 mL) solution was 
added, and the product was extracted using ethyl acetate (3×15 mL). The organic layers were 
combined, washed with brine, dried over Na2SO4, concentrated and purified using silica gel 
column chromatography, eluting with 5:1 dichloromethane-methanol, to provide 35 as white 
glass (55 mg, 25%). 1H NMR (300 MHz, methanol-d4, D2O) δ 7.36 (s, 1 H), 7.09-7.01 (m, 2 H), 
6.97-6.88 (m, 2 H), 6.84 (dq, J = 9.4, 2.6 Hz, 3 H), 6.81-6.73 (m, 2 H), 6.51-6.55 (m, 2 H), 6.50-
6.44 (m, 2 H), 6.41 (dt, J = 7.7, 1.3 Hz, 1 H), 4.89 (s, 2 H); 13C NMR (75 MHz, methanol-d4) δ 
158.13, 157.30, 148.54, 145.57, 142.46, 134.75, 134.59, 133.51, 132.90, 131.65, 130.01, 121.14, 
117.94, 116.32, 115.26, 52.44; ESIMS m/z (relative intensity) 384 (MH+, 28), 316 (100); 
negative ion HRESIMS m/z calcd for C24H21N3O2 [(M – H+)–] 382.1555, found 382.1563. HPLC 
purity: 100% (C-18 reverse phase, methanol-H2O, 90:10).  
Molecular Docking of Compounds 12 and 36 in the Active Site of Aromatase. The 
structures of compounds 12 and 36 were constructed with Sybyl 7.1 software and energy 
minimized to 0.01 kcal/mol by the Powell method using Gasteiger-Huckel charges and the 
Tripos force field. The crystal structure of aromatase was obtained from the Protein Data Bank 
(PDB ID: 3s79),33 and the natural ligand (androstenedione) and all crystal water molecules were 
removed. Compounds 12 and 36 were docked into the androstenedione binding pocket in 
aromatase using the GOLD 3.0 program. A distance constraint was added between the imidazole 
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nitrogen of 12 or 36 and the iron to confine the distance within 1.5-3.5 Å during docking. The 
best docking solutions according to the GOLD fitness scores were selected.  
Molecular Docking of Compound 12 in the Active Site of ER-α. The structure of 
compound 12 was constructed with Sybyl 7.1 software and energy minimized to 0.01 kcal/mol 
by the Powell method using Gasteiger-Huckel charges and the Tripos force field. The crystal 
structure of ER-α was obtained from the Protein Data Bank (PDB ID: 3ert),34 and the natural 
ligand (4-hydroxy tamoxifen) and all crystal water molecules (except the water that forms 
bifurcated hydrogen bonds with Glu353 and Arg394) were removed. Compound 12 was docked 
into the ligand binding pocket of ER-α using the GOLD 3.0 program. The best docking solution 
according to GOLD fitness score was selected.  
Inhibition of Recombinant Human Aromatase (CYP19) by Microsomal Incubations. 
The activity of recombinant aromatase (CYP19) was determined by measuring the conversion 
rate of the fluorometric substrate 7-methoxy-4-trifluoromethylcoumarin (MFC) to its fluorescent 
metabolite 7-hydroxytrifluoromethylcoumarin (HFC). Experimental procedures were consistent 
with the published methodology.37 All of the incubations were performed using incubation times 
and protein concentrations that were within the linear range for reaction velocity. The 
fluorometric substrate, MFC, was dissolved in acetonitrile with the final concentration of 25 
mM. All tested samples were dissolved in either methanol or DMSO. The sample solutions (2 
µL) were mixed well with 98 µL of NADPH-Cofactor Mix (16.25 µM NADP+, 825.14 µM 
MgCl2, 825.14 µM glucose-6-phosphate and 0.4 Units/mL glucose-6-phosphate dehydrogenase), 
and were pre-warmed for 10 min at 37 oC. Enzyme/substrate mix was prepared with fluorometric 
substrate, recombinant human aromatase (CYP19) and 0.1 M potassium phosphate buffer (pH 
7.4). Reactions were initiated by adding enzyme/substrate mix (100 µL) to bring the incubation 
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volume to 200 µL, and the mixture was incubated for 30 min. All the reactions were stopped by 
adding 0.1 M tris base dissolved in acetonitrile (75 µL). The amount of fluorescent product was 
determined immediately by measuring fluorescent response using a BioTek (Winooski, VT) 
Synergy 2 fluorometric plate reader. Excitation-emission wavelengths for MFC metabolite were 
409 and 530 nm. The standard curve for MFC metabolite was constructed using the appropriate 
fluorescent metabolite standards. Quantification of samples was performed by applying the linear 
regression equation of the standard curve to the fluorescence response. The limit of 
quantification for the metabolites of MFC was 24.7 pmol with intra- and inter-assay coefficients 
of variation less than 10%. The rates of metabolite formation in the presence of the test inhibitors 
were compared with those in the control, in which the inhibitor was replaced with vehicle. The 
extent of enzyme inhibition was expressed as the percentage of remaining enzyme activity 
compared to the control. IC50 values were determined as the inhibitor concentrations that brought 
about half reduction in enzyme activity by fitting all the data to a one-site competition equation 
using Graphpad Prism 5.0 (GraphPad Software Inc., San Diego, CA).  
Binding Affinities for Recombinant Human ER-α and ER-β. The binding affinities of 
ER-α and ER-β were determined by measuring the change of polarization value when the 
fluorescent estrogen ligand, ES2, was displaced by the tested compounds. Experimental 
procedures were consistent with the protocol provided by Invitrogen. The fluorescent estrogen 
ligand, ES2, was provided in methanol/water (4:1, v/v) at a concentration of 1800 nM. 
Recombinant human ER-α and ER-β were provided in buffer (50 mM bis-tris propane, 400 mM 
KCl, 2 mM DTT, 1 mM EDTA and 10% glycerol), at concentrations of 734 nM and 3800 nM, 
respectively. All tested samples were dissolved in either methanol or DMSO. The sample 
solutions (1 µL) were mixed well with 49 µL of ES2 screening buffer (100 mM potassium 
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phosphate, 100 µg/mL BGG and 0.02% NaN3). The ER-α/ES2 complex was prepared with the 
fluorescent estrogen ligand ES2, human recombinant ER and ES2 screening buffer at 
concentrations of 9 nM ES2 and 30 nM ER-α. The ER-β/ES2 complex was prepared with the 
fluorescent estrogen ligand ES2, human recombinant ER-β and ES2 screening buffer at 
concentrations of 9 nM ES2 and 20 nM ER-β. Reactions were initiated by adding ER/ES2 
complex (50 µL) to bring the incubation volume to 100 µL, and incubated for 2 h avoiding light. 
The polarization value was determined by measuring fluorescent response using a BioTek 
(Winooski, VT) Synergy 2 fluorometric plate reader. Excitation-emission wavelengths for 
fluorescence polarization were 485 and 530 nM. The polarization values in the presence of the 
test competitors were compared with those of the control, in which the competitor was replaced 
with vehicle. The extent of competition was expressed as the percentage of remaining 
polarization compared to the control. EC50 values were determined as the competitor 
concentrations that brought about half reduction in polarization value by fitting all the data to a 
one-site competition equation using Graphpad Prism 5.0 (GraphPad Software Inc., San Diego, 
CA).  
Cell Culture and Test Compound Treatment. Estrogen receptor-positive human breast 
carcinoma cell line (MCF-7 cells) were seeded at a density of 105 cells/well in 6-well plates and 
maintained at 37 oC under a humidified atmosphere of 5% CO2 and 95% air in minimum 
essential media (MEM) supplemented with 10% fetal bovine serum (FBS). Before the test 
compound treatments, the cells were preconditioned in charcoal-stripped FBS for 72 h to remove 
the estrogens from the growth medium containing 10% FBS. The cells were treated with vehicle 
(0.1%  methanol) alone, 1 µM test compound or 1 µM endoxifen (positive control) for 24 h in 
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the presence of 10 nM β-estradiol (E2) dissolved in MEM supplemented with 10% charcoal-
stripped FBS.  
Ribonucleic Acid (RNA) Extraction and Concentration Measurement. The MCF-7 
cells treated with test compounds or experimental controls for 24 h were harvested for 
progesterone receptor (PGR) messenger ribonucleic acid (mRNA) extraction. Before ribonucleic 
acid (RNA) extraction, genomic DNA was eliminated. RNA was extracted from approximately 
3×105 cells by RNeasy Plus Mini Kit (QiagenInc., Valencia, California, USA). The RNA 
concentration was measured using the Qubit RNA BR assay (Life Technologies Corp., Carlsbad, 
CA) for the Qubit 2.0 fluorometer (Life Technologies Corp., Carlsbad, CA). The RNA was 
stored at –80 oC before further use.  
Complementary Deoxyribonucleic Acid (cDNA) Synthesis. Complementary 
deoxyribonucleic acid (cDNA) for the real-time quantitative polymerase chain reaction (PCR) 
assay was synthesized from DNase-treated total RNA using the QuantiTect reverse transcription 
kit (QiagenInc., Valencia, California, USA).  
Real-Time Quantitative Polymerase Chain Reaction (PCR) for cDNA. The cDNA 
was amplified with TaqMan Universal PCR Master Mix (Applied Biosystems Inc., Carlsbad, 
CA),  and then PCR was performed in the QuantStudio 12K Flex Real-Time PCR System (Life 
Technologies Corp., Carlsbad, CA). Progesterone receptor gene (PGR, FAM, Hs01556702, Life 
Technologies Corp., Carlsbad, CA) was the target gene, while glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH, VIC, Hs02758991, Life Technologies Corp., Carlsbad, CA) gene 
expression was quantified to normalize each sample. A total of 40 amplification cycles were 
performed. Quantitative values of amplification were obtained from the threshold cycle (Ct) 
defined as the cycle number at which the fluorescent signal is first recorded above the 
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background as determined during the exponential phase of PCR rather than at the endpoint. The 
2-ΔΔCt method was used to determine the relative mRNA expression, and the results were 
expressed as percentages of antagonism effects compared to E2-stimulated PGR mRNA 
expression (considered as 100%). If amplification was not seen by 40 cycles, the measured RNA 
was considered to be undetectable.  
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tamoxifen, alone or in combination; ER, estrogen receptor; FDA, Food and Drug Administration; 
 
 
 
 
45 
MOMCl, methyl chloromethyl ether; NBS, N-bromosuccinimide; CYP, cytochrome P450; E2, β-
estradiol; PGR, progesterone receptor; PDB, protein data bank. 
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